-
1
-
-
0028779536
-
Bone marrow transplantation
-
Armitage JO: Bone marrow transplantation. N Engl J Med 330:827-838, 1994
-
(1994)
N Engl J Med
, vol.330
, pp. 827-838
-
-
Armitage, J.O.1
-
3
-
-
0036210985
-
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
-
Arai S, Margolis J, Zahurak M, et al: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8:155-160, 2002
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 155-160
-
-
Arai, S.1
Margolis, J.2
Zahurak, M.3
-
4
-
-
0034307671
-
Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study
-
Greinix HT, Volc-Platzer B, Knobler RM, et al: Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study. Blood 96:477A, 2000
-
(2000)
Blood
, vol.96
-
-
Greinix, H.T.1
Volc-Platzer, B.2
Knobler, R.M.3
-
5
-
-
0035496916
-
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL
-
Deeg HJ, Blazar BR, Bolwell BJ, et al: Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98:2052-2058, 2001
-
(2001)
Blood
, vol.98
, pp. 2052-2058
-
-
Deeg, H.J.1
Blazar, B.R.2
Bolwell, B.J.3
-
6
-
-
0037089222
-
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
-
Carpenter PA, Appelbaum FR, Corey L, et al: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99:2712-2719, 2002
-
(2002)
Blood
, vol.99
, pp. 2712-2719
-
-
Carpenter, P.A.1
Appelbaum, F.R.2
Corey, L.3
-
7
-
-
0025190044
-
Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome
-
Weisdorf D, Haake R, Blazar B, et al: Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 75:1024-1030, 1990
-
(1990)
Blood
, vol.75
, pp. 1024-1030
-
-
Weisdorf, D.1
Haake, R.2
Blazar, B.3
-
8
-
-
0026757709
-
Acute graft-versus-host disease following unrelated donor marrow transplantation: Failure of conventional therapy
-
Roy J, McGlave PB, Filipovich AH, et al: Acute graft-versus-host disease following unrelated donor marrow transplantation: Failure of conventional therapy. Bone Marrow Transplant 10:77-82, 1992
-
(1992)
Bone Marrow Transplant
, vol.10
, pp. 77-82
-
-
Roy, J.1
McGlave, P.B.2
Filipovich, A.H.3
-
9
-
-
0025731169
-
A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment
-
Martin PJ, Schoch G, Fisher L, et al: A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 77:1821-1828, 1991
-
(1991)
Blood
, vol.77
, pp. 1821-1828
-
-
Martin, P.J.1
Schoch, G.2
Fisher, L.3
-
10
-
-
0028010849
-
Newer purine analogues for the treatment of hairy-cell leukemia
-
Saven A, Piro L: Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 330:691-697, 1994
-
(1994)
N Engl J Med
, vol.330
, pp. 691-697
-
-
Saven, A.1
Piro, L.2
-
11
-
-
0015515283
-
Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity
-
Giblett ER, Anderson JE, Cohen F, et al: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067-1069, 1972
-
(1972)
Lancet
, vol.2
, pp. 1067-1069
-
-
Giblett, E.R.1
Anderson, J.E.2
Cohen, F.3
-
12
-
-
0023109354
-
Inhibition of lymphocyte-specific enzymes: A promising approach for selective immunosuppression
-
Ruers TJ, Buurman WA, van der Linden CJ, et al: Inhibition of lymphocyte-specific enzymes: A promising approach for selective immunosuppression. Transplant Proc 19:1287-1289, 1987
-
(1987)
Transplant Proc
, vol.19
, pp. 1287-1289
-
-
Ruers, T.J.1
Buurman, W.A.2
van der Linden, C.J.3
-
13
-
-
0026710706
-
Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo
-
Bagasra O, Howeedy A, Pomerantz RJ: Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo. Clin Exp Immunol 88:383-388, 1992
-
(1992)
Clin Exp Immunol
, vol.88
, pp. 383-388
-
-
Bagasra, O.1
Howeedy, A.2
Pomerantz, R.J.3
-
14
-
-
0020699835
-
Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine
-
Grever MR, Siaw MF, Coleman MS, et al: Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine. J Immunol 130:365-369, 1983
-
(1983)
J Immunol
, vol.130
, pp. 365-369
-
-
Grever, M.R.1
Siaw, M.F.2
Coleman, M.S.3
-
16
-
-
0031052623
-
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up
-
Seymour JF, Talpaz M, Kurzrock R: Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 11:42-47, 1997
-
(1997)
Leukemia
, vol.11
, pp. 42-47
-
-
Seymour, J.F.1
Talpaz, M.2
Kurzrock, R.3
-
17
-
-
0024595398
-
Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia
-
Urba WJ, Baseler MW, Kopp WC, et al: Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73:38-46, 1989
-
(1989)
Blood
, vol.73
, pp. 38-46
-
-
Urba, W.J.1
Baseler, M.W.2
Kopp, W.C.3
-
18
-
-
0023006839
-
Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pre-treatment with 2′-deoxycoformycin
-
Epstein J, Bealmear PM, Kennedy DW, et al: Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pre-treatment with 2′-deoxycoformycin. Exp Hematol 14:845-849, 1986
-
(1986)
Exp Hematol
, vol.14
, pp. 845-849
-
-
Epstein, J.1
Bealmear, P.M.2
Kennedy, D.W.3
-
19
-
-
2442642825
-
A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease
-
Miller KB, Roberts TF, Chan G, et al: A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant 33:881-889, 2004
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 881-889
-
-
Miller, K.B.1
Roberts, T.F.2
Chan, G.3
-
20
-
-
0019835363
-
Effect of 2′-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth
-
Aye MT, Dunne JV: Effect of 2′-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth. Blood 58:1043-1046, 1981
-
(1981)
Blood
, vol.58
, pp. 1043-1046
-
-
Aye, M.T.1
Dunne, J.V.2
-
21
-
-
0021321053
-
An enzymatic kinetic method for the determination of 2′-deoxycoformycin in biological fluids
-
Staubus AE, Weinrib AB, Malspeis L: An enzymatic kinetic method for the determination of 2′-deoxycoformycin in biological fluids. Biochem Pharmacol 33:1633-1637, 1984
-
(1984)
Biochem Pharmacol
, vol.33
, pp. 1633-1637
-
-
Staubus, A.E.1
Weinrib, A.B.2
Malspeis, L.3
-
22
-
-
0019127565
-
The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin
-
Smyth JF, Paine RM, Jackman AL, et al: The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 5:93-101, 1980
-
(1980)
Cancer Chemother Pharmacol
, vol.5
, pp. 93-101
-
-
Smyth, J.F.1
Paine, R.M.2
Jackman, A.L.3
-
23
-
-
0019521591
-
Clinical pharmacology of deoxycoformycin
-
Major PP, Agarwal RP, Kufe DW: Clinical pharmacology of deoxycoformycin. Blood 58:91-96, 1981
-
(1981)
Blood
, vol.58
, pp. 91-96
-
-
Major, P.P.1
Agarwal, R.P.2
Kufe, D.W.3
-
24
-
-
0019835982
-
Levels of 2′-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia
-
Venner PM, Glazer RI, Blatt J, et al: Levels of 2′-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res 41:4508-4511, 1981
-
(1981)
Cancer Res
, vol.41
, pp. 4508-4511
-
-
Venner, P.M.1
Glazer, R.I.2
Blatt, J.3
-
26
-
-
0021235975
-
Pharmacology of 2′-deoxycoformycin and vidarabine
-
Agarwal R: Pharmacology of 2′-deoxycoformycin and vidarabine. Cancer Treat Symp 2:17-22, 1984
-
(1984)
Cancer Treat Symp
, vol.2
, pp. 17-22
-
-
Agarwal, R.1
-
27
-
-
0027422366
-
Pentostatin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders
-
Brogden RN, Sorkin EM: Pentostatin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 46:652-677, 1993
-
(1993)
Drugs
, vol.46
, pp. 652-677
-
-
Brogden, R.N.1
Sorkin, E.M.2
-
28
-
-
0000099405
-
Clinical pharmacokinetics of 2′-deoxycoformycin in renal impairment
-
abstr 361
-
Grever M, Staubus A, Balcerzak S, et al: Clinical pharmacokinetics of 2′-deoxycoformycin in renal impairment. Proc Am Soc Clin Oncol 12:140, 1993 (abstr 361)
-
(1993)
Proc Am Soc Clin Oncol
, vol.12
, pp. 140
-
-
Grever, M.1
Staubus, A.2
Balcerzak, S.3
-
29
-
-
0033909539
-
Clinical pharmacokinetics of nucleoside analogues: Focus on haematological malignancies
-
Johnson S: Clinical pharmacokinetics of nucleoside analogues: Focus on haematological malignancies. Clin Pharmacokinet 39:5-26, 2000
-
(2000)
Clin Pharmacokinet
, vol.39
, pp. 5-26
-
-
Johnson, S.1
-
30
-
-
0028844579
-
Design and analysis of in vitro antitumor pharmacodynamic studies
-
Kalns JE, Millenbaugh NJ, Wientjes MG, et al: Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res 55:5315-5322, 1995
-
(1995)
Cancer Res
, vol.55
, pp. 5315-5322
-
-
Kalns, J.E.1
Millenbaugh, N.J.2
Wientjes, M.G.3
-
31
-
-
0032190104
-
Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation
-
Van Lint MT, Uderzo C, Locasciulli A, et al: Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 92:2288-2293, 1998
-
(1998)
Blood
, vol.92
, pp. 2288-2293
-
-
Van Lint, M.T.1
Uderzo, C.2
Locasciulli, A.3
-
32
-
-
0028227814
-
2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease
-
Pless M, Gratwohl A, Tichelli A, et al: 2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease. Blood 84:987-989, 1994
-
(1994)
Blood
, vol.84
, pp. 987-989
-
-
Pless, M.1
Gratwohl, A.2
Tichelli, A.3
-
33
-
-
0024590995
-
Pentostatin in the treatment of advanced hairy cell leukemia
-
Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 7:168-172, 1989
-
(1989)
J Clin Oncol
, vol.7
, pp. 168-172
-
-
Kraut, E.H.1
Bouroncle, B.A.2
Grever, M.R.3
-
34
-
-
0035383814
-
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
-
Storek J, Dawson MA, Storer B, et al: Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97:3380-3389, 2001
-
(2001)
Blood
, vol.97
, pp. 3380-3389
-
-
Storek, J.1
Dawson, M.A.2
Storer, B.3
-
35
-
-
0032726389
-
Persistent changes in the immune system 4-10 years after ABMT
-
Nordoy T, Kolstad A, Endresen P, et al: Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant 24: 873-878, 1999
-
(1999)
Bone Marrow Transplant
, vol.24
, pp. 873-878
-
-
Nordoy, T.1
Kolstad, A.2
Endresen, P.3
-
36
-
-
0037019138
-
Clinical practice. Long-term care after hematopoietic-cell transplantation in adults
-
Antin JH: Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med 347:36-42, 2002
-
(2002)
N Engl J Med
, vol.347
, pp. 36-42
-
-
Antin, J.H.1
-
37
-
-
0030851117
-
ATG plus corticosteroid therapy for acute graft-versus-host disease: Predictors of response and survival
-
Dugan MJ, DeFor TE, Steinbuch M, et al: ATG plus corticosteroid therapy for acute graft-versus-host disease: Predictors of response and survival. Ann Hematol 75:41-46, 1997
-
(1997)
Ann Hematol
, vol.75
, pp. 41-46
-
-
Dugan, M.J.1
DeFor, T.E.2
Steinbuch, M.3
-
38
-
-
17844362706
-
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin
-
Khoury H, Kashyap A, Adkins DR, et al: Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 27:1059-1064, 2001
-
(2001)
Bone Marrow Transplant
, vol.27
, pp. 1059-1064
-
-
Khoury, H.1
Kashyap, A.2
Adkins, D.R.3
-
40
-
-
0035660613
-
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
-
Benito AI, Furlong T, Martin PJ, et al: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72:1924-1929, 2001
-
(2001)
Transplantation
, vol.72
, pp. 1924-1929
-
-
Benito, A.I.1
Furlong, T.2
Martin, P.J.3
-
41
-
-
1642394033
-
Treatment of resistant acute and chronic graft versus host disease with mycophenolate mofetil
-
abstr
-
Abhyankar S, Godder K, Christiansen N. Treatment of resistant acute and chronic graft versus host disease with mycophenolate mofetil. Blood 92:340B, 1998 (abstr)
-
(1998)
Blood
, vol.92
-
-
Abhyankar, S.1
Godder, K.2
Christiansen, N.3
-
42
-
-
84871469628
-
Treatment of acute and chronic graft versus host disease with mycophenolate mofetil
-
Ilhan O, Celebi H, Aral M, et al: Treatment of acute and chronic graft versus host disease with mycophenolate mofetil. Blood 94:368B, 1999
-
(1999)
Blood
, vol.94
-
-
Ilhan, O.1
Celebi, H.2
Aral, M.3
|